We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association Between Interstitial Lung Abnormalities and All-Cause Mortality.
- Authors
Putman, Rachel K.; Hiroto Hatabu; Tetsuro Araki; Gudmundsson, Gunnar; Wei Gao; Mizuki Nishino; Yuka Okajima; Dupuis, Josée; Latourelle, Jeanne C.; Cho, Michael H.; El-Chemaly, Souheil; Coxson, Harvey O.; Celli, Bartolome R.; Fernandez, Isis E.; Zazueta, Oscar E.; Ross, James C.; Harmouche, Rola; José Estépar, Raúl San; Diaz, Alejandro A.; Sigurdsson, Sigurdur
- Abstract
<bold>Importance: </bold>Interstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total lung capacity. However, to our knowledge, an association with mortality has not been previously investigated.<bold>Objective: </bold>To investigate whether interstitial lung abnormalities are associated with increased mortality.<bold>Design, Setting, and Population: </bold>Prospective cohort studies of 2633 participants from the FHS (Framingham Heart Study; computed tomographic [CT] scans obtained September 2008-March 2011), 5320 from the AGES-Reykjavik Study (Age Gene/Environment Susceptibility; recruited January 2002-February 2006), 2068 from the COPDGene Study (Chronic Obstructive Pulmonary Disease; recruited November 2007-April 2010), and 1670 from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; between December 2005-December 2006).<bold>Exposures: </bold>Interstitial lung abnormality status as determined by chest CT evaluation.<bold>Main Outcomes and Measures: </bold>All-cause mortality over an approximate 3- to 9-year median follow-up time. Cause-of-death information was also examined in the AGES-Reykjavik cohort.<bold>Results: </bold>Interstitial lung abnormalities were present in 177 (7%) of the 2633 participants from FHS, 378 (7%) of 5320 from AGES-Reykjavik, 156 (8%) of 2068 from COPDGene, and in 157 (9%) of 1670 from ECLIPSE. Over median follow-up times of approximately 3 to 9 years, there were more deaths (and a greater absolute rate of mortality) among participants with interstitial lung abnormalities when compared with those who did not have interstitial lung abnormalities in the following cohorts: 7% vs 1% in FHS (6% difference [95% CI, 2% to 10%]), 56% vs 33% in AGES-Reykjavik (23% difference [95% CI, 18% to 28%]), and 11% vs 5% in ECLIPSE (6% difference [95% CI, 1% to 11%]). After adjustment for covariates, interstitial lung abnormalities were associated with a higher risk of death in the FHS (hazard ratio [HR], 2.7 [95% CI, 1.1 to 6.5]; P = .03), AGES-Reykjavik (HR, 1.3 [95% CI, 1.2 to 1.4]; P < .001), COPDGene (HR, 1.8 [95% CI, 1.1 to 2.8]; P = .01), and ECLIPSE (HR, 1.4 [95% CI, 1.1 to 2.0]; P = .02) cohorts. In the AGES-Reykjavik cohort, the higher rate of mortality could be explained by a higher rate of death due to respiratory disease, specifically pulmonary fibrosis.<bold>Conclusions and Relevance: </bold>In 4 separate research cohorts, interstitial lung abnormalities were associated with a greater risk of all-cause mortality. The clinical implications of this association require further investigation.
- Subjects
CORONARY disease; CAUSES of death; PULMONARY emphysema; LONGITUDINAL method; OBSTRUCTIVE lung diseases; SMOKING; TUMORS; DISEASE prevalence; PROPORTIONAL hazards models
- Publication
JAMA: Journal of the American Medical Association, 2016, Vol 315, Issue 7, p672
- ISSN
0098-7484
- Publication type
journal article
- DOI
10.1001/jama.2016.0518